Pre-market: CVS.DE (CVS Health) down 11.99% to €61.34 on XETRA 28 Jan 2026: Medicare-rate risk pressures outlook
CVS.DE stock slid 11.99% pre-market to €61.34 on XETRA on 28 Jan 2026 after headlines pointed to a proposed flat Medicare Advantage rate, which markets view as a revenue headwind for large insurers and PBMs. The move followed an open at €64.84 versus a previous close of €69.70, and came on light volume of 2,245 shares. We review drivers, valuation, technical levels and Meyka AI model forecasts to explain why the drop makes CVS.DE stock one of today’s top losers and what traders should watch next.
Price action and key metrics for CVS.DE stock
CVS.DE stock is trading €61.34, down €8.36 or 11.99% pre-market on XETRA. One-day range is €61.34–€64.85, year range €50.05–€73.65, and average volume is 384 versus current 2,245, giving a relative volume of 5.57. Important fundamentals: EPS €0.32, P/E 191.69, market cap €77,866,988,630, and dividend yield about 3.72%. Each figure connects directly to valuation pressure after the Medicare-rate news.
Why the drop: policy and sector drivers for CVS.DE stock
Investors cited a proposed federal decision to keep Medicare Advantage rates broadly flat, hitting expected revenue for Health Care Benefits and Pharmacy Services. The Healthcare sector in Germany shows modest YTD strength but insurer-linked names reacted poorly, increasing downside risk for CVS.DE stock. Recent news coverage from MarketBeat and a market summary on Investing.com framed the move.
Meyka AI rates CVS.DE with a score out of 100: grade and what it means
Meyka AI rates CVS.DE with a score out of 100: 67.76 (Grade B, HOLD). This grade factors S&P 500 comparison, sector and industry metrics, financial growth, key ratios, forecasts and analyst inputs. The grade balances solid cash flow metrics and a €2.74 dividend per share against high leverage (debt/equity 1.12) and weak margins. These grades are not guaranteed and we are not financial advisors.
Valuation and risk metrics for CVS.DE stock
Valuation shows mixed signals: price-to-sales 0.24, price-to-book 1.28, and p/fcf 14.84 contrast with a stretched P/E near 191.69 driven by depressed earnings. Interest coverage is 1.59, net-debt-to-EBITDA near 6.85, and current ratio 0.83, highlighting liquidity and leverage risks. Short-term support sits near today’s low €61.34 and the 200-day average is €62.17; a break below could expose the €50.05 year low.
Technicals and trading levels for CVS.DE stock
Momentum indicators are neutral to mixed: RSI 54.24, MACD histogram 0.23, ATR 1.07. The 50-day average (€67.76) and Bollinger middle (€67.59) act as near resistance. On higher timeframe the 200-day mean (€62.17) is a key level. Traders should note low intraday liquidity on XETRA and a sharp gap risk given relative volume 5.57.
Analyst context, forecasts and price targets for CVS.DE stock
There is limited public price-target consensus on the XETRA listing. Meyka AI’s forecast model projects a yearly level at €72.70 and a quarterly median near €79.92, implying upside from current levels. Short-term analyst sentiment is cautious after the Medicare-rate headlines; any confirmed guidance cut at the earnings announcement on 10 Feb 2026 would push many models lower.
Final Thoughts
The pre-market sell-off leaves CVS.DE stock down 11.99% at €61.34 and flags policy sensitivity for a large US healthcare operator listed on XETRA in Germany. Key takeaways: momentum is weak intraday, leverage and margins are the primary structural risks, and dividend yield near 3.72% offers income support if cash flow holds. Meyka AI’s forecast model projects a one-year level of €72.70, implying about 19.35% upside from €61.34, but that projection is model-based and not a guarantee. We keep the Meyka AI grade at 67.76 (B, HOLD) reflecting mixed fundamentals and sector headwinds. Watch upcoming earnings on 10 Feb 2026, the company’s commentary on Medicare-rate exposure, and a sustained close below the €62.17 200-day average for a potential shift to a more bearish scenario. For real-time updates, use our Meyka AI-powered market analysis platform and recheck volume and guidance before trading.
FAQs
Why did CVS.DE stock drop today?
CVS.DE stock fell on 28 Jan 2026 after reports the government may keep Medicare Advantage rates roughly flat, which lowers expected revenue for benefits and PBM segments and prompted investor selling.
What is Meyka AI’s view and grade for CVS.DE stock?
Meyka AI rates CVS.DE with a score out of 100: 67.76 (Grade B, HOLD). The grade balances cash flow strength against high leverage and margin pressure; grades are model outputs and not investment advice.
What price levels should traders watch for CVS.DE stock?
Key levels: immediate support €61.34, 200-day average €62.17, 50-day average €67.76, and model one-year forecast €72.70. A clear break below €61.00 raises risk toward the year low €50.05.
How does the Medicare-rate news affect CVS.DE earnings and outlook?
Flat Medicare Advantage rates would weigh on the Health Care Benefits segment and could reduce guidance; that prospect drove the Jan 28 move and increases uncertainty ahead of 10 Feb 2026 earnings.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
